my personal edition > nutritional / metabolic other > news


  E-Mail this DGNews to a colleague

DGNews

New Study Finds Omega-3's in Fatty Fish Can Reduce Risk of Cancer

Omega-3's in Animi-3 Rx Address Dietary Deficiency That May Cause Cancer

GORDONSVILLE, VA -- September 26, 2006 -- A new study conducted by scientists at the Karolinska Institutet in Sweden has found that eating fatty fish, which contains higher levels of DHA* and EPA** (omega-3's) than lean fish, significantly decreases the risk of renal cell carcinoma (RCC) in women.

Published in the Journal of the American Medical Association, the study is the first to address RCC, which accounts for 80% of all kidney cancers. RCC has been on the rise in the United States.

"This is the first time that a link between the consumption of fatty fish and renal cancer has been studied," said Professor Alicja Wolk, principal investigator of the study. "The reason previous studies have been unable to demonstrate a link between fish consumption and renal cancer is that they made no distinction between fatty and non-fatty fish."***

Researchers analyzed data from the Swedish Mammography Cohort, a population-based study of 61,433 women without previous diagnosis of cancer at baseline (1987-1990). Participants completed two food frequency questionnaires -- one at baseline with a mammography, and another in September 1997.

"At least one portion of fatty fish a week during the period (1987-2004) reduced the risk of renal cancer by 74 per cent compared with those who never ate fatty fish. The group who ate fresh fish at least once a week but for whom follow-up information were unavailable, saw a 40 per cent reduction."***

Statistics confirm that Americans have the lowest intake of omega-3 of any developed country. Studies published in peer-reviewed journals have reported that patients with an array of diseases may be deficient in omega-3, folic acid, and vitamins B6 and B12.

Doctors are now using Animi-3 (http://www.animi-3.com) to reliably deliver, in a controlled, predictable manner, omega-3 to different types of patients. The omega-3 in Animi-3 meets the highest purity requirements and has no mercury or other harmful contaminants.

"This is an exciting and provocative finding that warrants continued research, particularly with a compound such as Animi-3, which is virtually contaminant-free," said Dr. Barbara Levine, Director of Clinical Nutrition at Strang Cancer Prevention Center, Weill College of Medicine of Cornell University. "In fact, we are currently planning studies at Strang on omega-3 fatty acids in colon and breast cancer models."

"This study suggests by implication that Animi-3 may be used in supplementing the overall intake of omega-3 fatty acids as well as B vitamins for those who cannot consume enough oily fish," said Jack Schramm, PBM Pharmaceuticals EVP and inventor of Animi-3. "Moreover, our omega-3's have been highly refined to remove contaminants commonly found in fish such as methylmercury and PCBs."

*docosahexaenoic acid

**eicosapentaenoic acid

***Karolinska Institutet press release. September 20, 2006.

JAMA. 2006;296:1371-1376.


SOURCE: PBM Pharmaceuticals, Inc.

E-Mail this DGNews to a colleague

To print, use this version